BIVI BioVie Inc. - Common stock
NASDAQ · Biotechnology close Oct 2, 2026BIVI Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
BIVI Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| July 7, 2025 | 1-for-10 | Reverse |
| Aug. 6, 2024 | 1-for-10 | Reverse |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| March 31, 2026 | $-0.70 | $-0.74 | 6.0% | |
| March 31, 2025 | $-0.15 | $-0.17 | 13.5% | |
| Dec. 31, 2024 | $-0.46 | $-0.16 | -181.9% | |
| Dec. 31, 2023 | $-22.00 | $-32.33 | 32.0% | |
| Sept. 30, 2023 | $-29.00 | $-31.62 | 8.3% |
Institutional owners (13F) 37 filers · $3.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (-3 vs prior Q) | 3 (-3 vs prior Q) | 8 (+1 vs prior Q) | 11 (+6 vs prior Q) | +441K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| MORGAN STANLEY | $1,174,614 | 605,471 | 39.40% | Shares |
| Diametric Capital, LP | $497,873 | 256,636 | 16.70% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $248,161 | 127,918 | 8.32% | Shares |
| VANGUARD GROUP INC | $247,696 | 213,531 | 8.31% | Shares |
| CITADEL ADVISORS LLC | $186,147 | 95,952 | 6.24% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $137,558 | 70,906 | 4.61% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $137,257 | 70,752 | 4.60% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $72,861 | 37,557 | 2.44% | Shares |
| JANE STREET GROUP, LLC | $69,569 | 35,860 | 2.33% | Shares |
| PRELUDE CAPITAL MANAGEMENT, LLC | $63,211 | 32,583 | 2.12% | Shares |
| NORTHERN TRUST CORP | $42,331 | 21,820 | 1.42% | Shares |
| Persistent Asset Partners Ltd | $29,092 | 14,996 | 0.98% | Shares |
| XTX Topco Ltd | $27,602 | 14,228 | 0.93% | Shares |
| Caprock Group, LLC | $21,922 | 11,300 | 0.74% | Shares |
| Allworth Financial LP | $10,864 | 5,600 | 0.36% | Shares |
| UBS Group AG | $4,220 | 2,175 | 0.14% | Shares |
| Tower Research Capital LLC (TRC) | $4,004 | 2,064 | 0.13% | Shares |
| CIBC Private Wealth Group LLC | $2,084 | 1,097 | 0.07% | Shares |
| PNC Financial Services Group, Inc. | $1,940 | 1,000 | 0.07% | Shares |
| SBI Securities Co., Ltd. | $1,682 | 867 | 0.06% | Shares |
| PHILADELPHIA TRUST CO | $97 | 50,010 | 0.00% | Shares |
| Cambridge Investment Research Advisors, Inc. | $27 | 13,816 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $27 | 14 | 0.00% | Shares |
| Tradewinds Capital Management, LLC | $20 | 10 | 0.00% | Shares |
| WELLS FARGO & COMPANY/MN | $19 | 10 | 0.00% | Shares |
| NewEdge Advisors, LLC | $19 | 10 | 0.00% | Shares |
| OSAIC HOLDINGS, INC. | $15 | 8 | 0.00% | Shares |
| Financial Perspectives, Inc | $12 | 6 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $10 | 5 | 0.00% | Shares |
| FIFTH THIRD BANCORP | $8 | 4 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $6 | 3 | 0.00% | Shares |
| GILL CAPITAL PARTNERS, LLC | $4 | 2 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $2 | 1 | 0.00% | Shares |
| DANSKE BANK A/S | $2 | 1 | 0.00% | Shares |
| ALBION FINANCIAL GROUP /UT | $2 | 1 | 0.00% | Shares |
| FMR LLC | $2 | 1 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 200 | 0.00% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Acuitas Group Holdings, LLC (2), Terren S. Peizer (2) ×5 filings | June 25, 2024 | · | Initial filing | · | SEC |
| Acuitas Group Holdings, LLC, Terren S. Peizer ×5 filings | June 11, 2021 | · | Initial filing | M&A / sale | SEC |
| ACUITAS GROUP HOLDINGS , LLC, Terren S. Peizer | July 3, 2018 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 20 insiders · 8 officers · 13 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| DO CUONG V | President & CEO | Jan. 5, 2026 A | 9,992 | 0 | 0 | $0 |
| Joanne Wendy Kim | Chief Financial Officer | Jan. 5, 2026 A | 93,940 | 0 | 0 | $0 |
| Richard R Wieland | interim CFO | Oct. 25, 2017 A | · | 0 | 0 | $0 |
| Joseph M Palumbo | Chief Medical Officer | Jan. 5, 2026 A | 119,196 | 0 | 0 | $0 |
| Clarence N. Ahlem | EVP Neuroscience Product Dev. | Feb. 16, 2023 F | 37,148 | 0 | 0 | $0 |
| Penelope Markham | EVP Liver Cirrhosis R&D | Feb. 16, 2023 F | 47,841 | 0 | 0 | $0 |
| Christopher Reading | EVP Neuroscience R&D | Feb. 16, 2023 F | 37,148 | 0 | 0 | $0 |
| Jonathan M Adams | EVP Liver Cirrhosis Programs | Feb. 2, 2022 G | 48,630 | 0 | 0 | $0 |
| Kameel D. Farag | Director | Jan. 5, 2026 A | · | 0 | 0 | $0 |
| Amy Suzon Chappell | Director | Jan. 5, 2026 A | · | 0 | 0 | $0 |
| Michael Edward Sherman | Director | Jan. 5, 2026 A | 718,181 | 0 | 0 | $0 |
| James Paul Lang | Director | Jan. 5, 2026 A | 68,622 | 0 | 0 | $0 |
| Sigmund Rogich | Director | Jan. 5, 2026 A | 36,926 | 0 | 0 | $0 |
| Robert J Hariri | Director | Dec. 20, 2024 A | 42,254 | 0 | 0 | $0 |
| Richard J Berman | Director | Dec. 20, 2024 A | 40,643 | 0 | 0 | $0 |
| Steve Gorlin | Director | Dec. 1, 2023 S | 46,358 | 0 | 0 | $0 |
| TERREN S. PEIZER | Director | Nov. 23, 2022 A | 19,529,846 | 0 | 0 | $0 |
| Sooch Mina | Director | Jan. 2, 2019 A | 813,636 | 0 | 0 | $0 |
| Hari Kumar | Director | Jan. 2, 2019 A | 727,272 | 0 | 0 | $0 |
| Julie G Anderson | Director | March 14, 2018 A | 368,500 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 70,906 SH | Aug. 19, 2026 | Daily |
BIVI Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
2 analysts · 2026-10-03Mean target $5.25 +259.9%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.